Sanofi’s Dupixent sales continue to deliver as ‘negative buzz’ impacts vaccine franchise

Sanofi posted robust third-quarter sales on Friday, backed by the continued growth of its blockbuster drug Dupixent. But the French pharma said its Q3 vaccine sales dipped about 8% from the ...